Domain Therapeutics

Domain Therapeutics receives $230K grant from Michael J. Fox Foundation

Monday, April 14, 2014

Domain Therapeutics, a biopharmaceutical company specializing in the R&D of new drug candidates targeting G protein-coupled receptors (GPCRs), has received a second grant of $230,000from the Michael J. Fox Foundation(MJFF) for Parkinson’s research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program. The MJFF first supported the initial stages of this program in 2012 with a $300,000 grant.

[Read More]